TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patients with Ph+ B-precursor ALL, with any of the following:~  * Relapsed or refractory to at least one second generation tyrosine kinase inhibitor (TKI) (dasatinib, nilotinib, bosutinib, ponatinib)~ * OR intolerant to second generation TKI and intolerant or refractory to imatinib mesylate~* Greater than 5% blasts in bone marrow~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Age ≥ 18 years of age, at the time of informed consent.~* Subject has provided informed consent or subject's legally acceptable representative has provided informed consent when the subject has any kind of condition that, in the opinion of the Investigator, may compromise the ability of the subject to give written informed consent.~Exclusion Criteria~* History of malignancy other than ALL within 5 years prior to start of protocol-required therapy, except for adequately treated selected cancers without evidence of disease~* History or presence of clinically relevant central nervous system (CNS) pathology as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis~* Active ALL in the CNS or testes~* Isolated extramedullary disease~* Current autoimmune disease or history of autoimmune disease with potential CNS involvement~* Allogeneic hematopoietic stem cell transplantation (HSCT) within 12 weeks before blinatumomab treatment~* Active acute or extensive chronic graft-versus-host disease (GvHD) which included the administration of immunosuppressive agents to prevent or treat GvHD within 2 weeks before blinatumomab treatment~* immediately previous cancer chemotherapy, radiotherapy, or immunotherapy; and eligibility for allogeneic HSCT at the time of enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinatumomab (Type: EXPERIMENTAL): Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age 18 years and above.~* Diagnosis of AD as defined by the Hanifin and Rajka 1980 criteria for AD.~* History of AD for ≥1 year.~* AD involvement of 5-50% treatable body surface area at screening and at baseline (excluding scalp).~* Disease severity graded as mild to severe according to vIGA-AD (i.e. vIGA-AD ≥2) at screening and baseline.~Key Exclusion Criteria:~* AD lesion(s) on scalp at screening and/or baseline.~* Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment, such as scabies, cutaneous lymphoma, rosacea, urticaria, or psoriasis.~* Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of severity of AD.~* Use of tanning beds or phototherapy within 4 weeks prior to baseline.~* Systemic treatment with immunosuppressive/modulating drugs or corticosteroids within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline.~* Treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase-4 inhibitors, or oral antibiotics within 2 weeks prior to baseline.~* Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e. the subjects must not start antihistamine treatment or change the current dosage regime within 2 weeks prior to baseline.~* Receipt of live attenuated vaccines within 4 weeks prior to baseline.~* Treatment with any marketed or investigational biologic agents within 6 months or 5 half-lives prior to baseline, or until cell counts return to normal, whichever is longer.~* History of any active skin infection within 1 week prior to baseline.~* Clinically significant infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Delgocitinib cream 1 mg/g (Type: EXPERIMENTAL): Delgocitinib cream applied twice daily for 8 weeks
- Delgocitinib cream 3 mg/g (Type: EXPERIMENTAL): Delgocitinib cream applied twice daily for 8 weeks
- Delgocitinib cream 8 mg/g (Type: EXPERIMENTAL): Delgocitinib cream applied twice daily for 8 weeks
- Delgocitinib cream 20 mg/g (Type: EXPERIMENTAL): Delgocitinib cream applied twice daily for 8 weeks
- Delgocitinib cream vehicle (Type: PLACEBO_COMPARATOR): Delgocitinib cream vehicle applied twice daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endotracheal Tube Holder and Bite Guard Research

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* General anesthesia requiring oral endotracheal intubation in the prone position for the duration of surgery (head secured in a foam head holder, horseshoe frame, or Mayfield pins).~* General anesthesia for neurosurgery requiring oral endotracheal intubation, supine or slight lateral bump position for the duration of surgery. (Special emphasis will be placed on including patients who will undergo motor evoked potentials, and thus will not be paralyzed during the surgery).~* General anesthesia requiring oral endotracheal intubation with a left sided double-lumen endotracheal tube for lung isolation, lateral position for the duration of surgery.~Exclusion Criteria:~* Dentition issues (loose teeth, missing teeth)~* Temporomandibular joint disease~* Maxillofacial abnormalities (deformities of the jaw, lips, tongue)~* Surgical procedures involving the teeth, lips, jaw~* History of asthma or bronchospasm~* Immunosuppression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETT holder and bite guard (Type: EXPERIMENTAL): Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants of 6 weeks of age (+7 days) on date of first vaccination~2. Healthy assessed from medical history and physical examination~3. One parent/guardian has been properly informed about the trial and has signed the informed consent form~4. One parent/guardian grants access to the infant's trial related medical records~5. One parent/guardian is likely to comply with trial procedures~Exclusion Criteria:~1. Vaccinated with poliovirus vaccine (OPV or IPV), other than the trial vaccines, prior to inclusion or planned during the trial (e.g. on national polio immunisation days)~2. OPV vaccination or known exposure to poliovirus in household (living together) within 3 month prior to inclusion or planned during the trial~3. Has a sibling who is ≤5 years of age, and for whom OPV vaccination is planned during the trial~4. Low birth weight (\< 2,500 g)~5. Known or suspected immunodeficiency (e.g. HIV, leukaemia, lymphoma) or family history of congenital or hereditary immunodeficiency~6. Severe uncontrolled chronic disease (e.g. neurologic, pulmonary, gastrointestinal, hepatic, renal or endocrine)~7. Known or suspected allergy to vaccine constituents (e.g. hypersensitivity to formaldehyde)~8. Acute severe febrile illness at day of vaccination deemed by the investigator to be a contraindication for vaccination~9. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections or blood sampling~10. Treatment with a product which is likely to modify the immune response (e.g. blood products and immunoglobulins) prior to inclusion or planned during the trial~11. Participating in another clinical trial~12. Not suitable for inclusion in the opinion of the investigator

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 49 Days
- Healthy Volunteers: t

Study Arms:
- 1/3 IPV-Al SSI (Type: EXPERIMENTAL): 3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
- 1/5 IPV-Al SSI (Type: EXPERIMENTAL): 3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
- 1/10 IPV-Al SSI (Type: EXPERIMENTAL): 3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
- IPV Vaccine SSI (Type: ACTIVE_COMPARATOR): 3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Value of Adding Either Meperdine or Fentanyl to Clonidine-bupivacaine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ASA I, II.~* Elective orthopedic lower limb surgery~Exclusion Criteria:~* Patients will be excluded from the study if their preoperative medication included opioid or non-opioid analgesics, corticosteroids, or non-steroidal anti-inflammatory drugs. Coagulation disorders, pregnancy, age less than 18 year, patient refusal, and emergency re-operation within the first 24hours also were exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Meperdine group (Type: ACTIVE_COMPARATOR): 15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
- Fentanyl group (Type: ACTIVE_COMPARATOR): 15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hemangioma patient ( 0 \~ 9 months old)~* No treatment before~* 10 \~ 20 % volume increase in 2 \~ 4 weeks~* Hemangioma that caused organ function~* Hemangioma that will cause aesthetic problem~Exclusion Criteria:~* Cardiovascular disease (impossible to use propranolol)~* Drug adverse reaction or allergy history (propranolol, steroid)~* Bradycardia, Atrioventricular block, atrial block~* Cardiogenic Shock~* Right heart failure (pulmonary hypertension)~* Congestive heart failure~* Hypotension~* Peripheral nerve disease (moderate)~* Angina~* Hormone deficiency patient~* Pulmonary disease (asthma)~* diabetic ketoacidosis~* laser treatment history

- Gender: ALL
- Minimum Age: None
- Maximum Age: 9 Months
- Healthy Volunteers: f

Study Arms:
- Prednisolone (Type: ACTIVE_COMPARATOR): Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
- Propranolol (Type: EXPERIMENTAL): Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must complete the double-blind base study (MK-0431-064-00)(NCT00397631) and have at least 75% compliance with study medication during the base study treatment period.~* Women of childbearing potential must continue to comply with the protocol-specified contraceptive methods

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin + Pioglitazone (Type: EXPERIMENTAL): None
- Pioglitazone + Placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of the Infant Truview EVO2 Video Laryngoscope and the Macintosh Laryngoscope in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age less than one year~2. Requiring general anesthesia and orotracheal intubation~3. Weight less than 10 kg~4. ASA class 1-3~Exclusion Criteria:~1. Documented difficult airway~2. Facial deformities

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- Truview intubation (Type: EXPERIMENTAL): Receive laryngoscopy with Truview first and is immediately followed by laryngoscopy and intubation with Macintosh
- Macintosh intubation (Type: ACTIVE_COMPARATOR): Macintosh blade will be used first followed by laryngoscopy and intubation with the truview

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Cohort A: Completion of 30 months of study treatment on Pfizer Protocol B3461028~Cohort B: Patients in specific countries diagnosed with ATTR-CM who did not previously participate in Pfizer Study B3461028~Exclusion Criteria:~-Liver and/or heart transplant, or implanted cardiac mechanical assist device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tafamidis (Type: EXPERIMENTAL): Active treatment - 61 mg or if not available, tafamidis megulmine 80 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Sleep Problems in VA Adult Day Health Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All of the following:~* ADHC program participant~* Age \>= 60 years~* Ability to communicate verbally~Exclusion Criteria:~One or more of the following:~* Significant cognitive impairment (Mini Mental State Examination score\<20)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SIP group (Type: EXPERIMENTAL): The Sleep Intervention Program group received a sleep education program based on behavioral principles, delivered in 4 individual sessions carried out within the Adult Day Health Care program.
- Control group (Type: ACTIVE_COMPARATOR): The Control group received basic sleep education, delivered in 4 individual sessions carried out within the Adult Day Health Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with proven tumor of RCC, MCL or GIST by histology.~* Informed consent signed by patient.~Exclusion Criteria:~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
- 2 (Type: None): Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
- 3 (Type: None): Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
- 4 (Type: None): Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
- 5 (Type: None): Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral-only Antibiotics for Bone and Joint Infections in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 3 months to 18 years with antibiotic treatment of uncomplicated bone or joint infection.~Exclusion Criteria:~1. Severe disease, e.g. septic shock, or any concomitant infection, e.g. necrotizing fasciitis, requiring IV antibiotics in the opinion of the treating clinician.~2. Complicated bone or joint infection, e.g. prosthetic material, infection secondary to or complicated by trauma, severe pyomyositis or other substantial soft tissue infections.~3. Expected need of major surgery within the first 24 hours of treatment, e.g. drilling, debridement, fenestration, surgical drainage, synovectomy. Minor surgery as diagnostic surgical bone biopsy or diagnostic joint fluid aspiration including lavage is not a criterion for exclusion.~4. Significant co-morbidities that might influence the choice of treatment or the course of the infection, e.g. immunodeficiency, immunosuppressive therapy, sickle cell anemia.~5. Previous bone or joint infection.~6. Antibiotic therapy for more than 24 hours before inclusion.~7. Documented pathogen with limited treatment options that do not permit randomization, e.g. the pathogen is only sensitive to intravenous antibiotics.~8. Prior enrolment in the trial

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: ACTIVE_COMPARATOR): \< 5 years: High-dose oral co-amoxiclav (1:8) 33 mg amoxicillin/kg/dose (max. 1 g) three-times daily (TDS) until clinical and paraclinical improvement (min. 3 days) followed by oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~=/\> 5 years: High-dose oral dicloxacillin 50 mg/kg/dose (max. 2 g) four-times daily (QID) until clinical and paraclinical improvement (min. 3 days) followed by oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings.
- Standard (Type: ACTIVE_COMPARATOR): IV ceftriaxon 100 mg/kg/dose (max. 4 g) once daily (QD) (all ages) until clinical and paraclinical improvement (min. 3 days) followed by:~\< 5 years: Oral co-amoxiclav (1:4) 17 mg amoxicillin/kg/dose (max. 500 mg) TDS for 7 days (arthritis) or 21 days (osteomyelitis).~\>/= 5 years: Oral dicloxacillin 25 mg/kg/dose (max. 1 g) QID for 7 days (arthritis) or 21 days (osteomyelitis).~Treatment will be adjusted according to microbiological findings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete